首页|Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer:Treatment Pattern and Survival Analysis of a 20-Year Real-World Study

Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer:Treatment Pattern and Survival Analysis of a 20-Year Real-World Study

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:To describe the treatment patterns and survival status of advanced gastric cancer(AGC)in China in the past two decades,and objectively evaluate the impact of standardized Chinese medicine(CM)treatment on the survival of AGC patients.Methods:This multicenter registry designed and propensity score analysis study described the diagnosis characteristics,treatment-pattern development and survival status of AGC from 10 hospitals in China between January 1,2000 and July 31,2021.Overall survival(OS)was evaluated between non-CM cohort(standard medical treatment)and CM cohort(integrated standard CM treatment ≥3 months).Propensity score matching(PSM)and inverse probability of treatment weighting(IPTW)were performed to adjust any difference in average outcomes for bias.Results:A total of 2,001 patients histologically confirmed locally advanced and/or metastasis stomach and gastroesophageal junction adenocarcinoma were enrolled.Among them,1,607 received systemic chemotherapy,215(10.74％)accepted molecular targeted therapy,44(2.2％)received checkpoint inhibitor therapy,and 769(38.43％)received CM.Two-drug regimen was the main choice for first-line treatment,with fluoropyrimidine plus platinum as the most common regimen(530 cases,60.09％).While 45.71％(16 cases)of patients with HER2 amplification received trastuzumab in first-line.The application of apatinib increased(33.33％)in third-line.The application of checkpoint inhibitors has increased since 2020.COX analysis showed that Lauren mixed type(P=0.017),cycles of first-line treatment＞6(P=0.000),CM(P=0.000),palliative gastrectomy(P=0.000),trastuzumab(P=0.011),and apatinib(P=0.008)were independent prognostic factors for the OS of AGC.After PSM and IPTW,the median OS of CM cohort and non-CM cohort was 18.17 and 12.45 months,respectively(P＜0.001).Conclusions:In real-world practice for AGC in China,therapy choices consisted with guidelines.Two-drug regimen was the main first-line choice.Standardized CM treatment was an independent prognostic factor and could prolong the OS of Chinese patients with AGC.(Registration No.NCT02781285)

advanced gastric cancerreal-world studytreatment patternsurvival analysisChinese medicine

CAO Ni-da、ZHU Xiao-hong、MA Fang-qi、XU Yan、DONG Jia-huan、QIN Meng-meng、LIU Tian-shu、ZHU Chun-chao、GUO Wei-jian、DING Hong-hua、GUO Yuan-biao、LIU Li-kun、SONG Jin-jie、WU Ji-ping、CHENG Yue-lei、ZENG Lin、ZHAO Ai-guang

展开 >

Oncology Department Ⅰ,Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai(200032),China

Oncology Department,Zhongshan Hospital,Fudan University,Shanghai(200032),China

Gastrointestinal Surgery Department,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai(200127),China

Oncology Department,Fudan University Shanghai Cancer Center,Shanghai(200032),China

Oncology Department,Shanghai General Hospital,Shanghai Jiaotong University School of Medicine,Shanghai(200080),China

Traditional Chinese Medicine Department,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai(200025),China

Oncology Department,Shanxi Traditional Chinese Medicine Hospital,Taiyuan(030012),China

Oncology Department,Xiyuan Hospital,China Academy of Chinese Medical Science,Beijing(102445),China

Oncology Department,Yunnan Province Hospital of Traditional Chinese Medicine,Kunming(650021),China

Oncology Department,Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai(201203),China

Shanghai NewCore Biotechnology Co.,Ltd.,Shanghai(200240),China

展开 >

国家自然科学基金"Three-Year Action Plan"of Shanghai Traditional Chinese Medicine Development Office of Shanghai Health CommissionShanghai"Science and Technology Innovation Action Plan"Medical Innovation Research ProjectShanghai Clinical Research Center of Traditional Chinese Medicine Oncology

82004133ZY3-CCCX-3-200321MC1930500

2024

10.1007/s11655-024-4107-8

中国结合医学杂志(英文版)
中国中西医结合学会 中国中医研究院

中国结合医学杂志(英文版)

CSTPCD
影响因子：1.056
ISSN：1672-0415
年,卷(期)：2024.30(6)
  • 40